Published in Drug Metab Rev on January 01, 2007
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem (2007) 1.47
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol (2009) 1.46
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos (2009) 1.26
Stable isotopic labelling-assisted untargeted metabolic profiling reveals novel conjugates of the mycotoxin deoxynivalenol in wheat. Anal Bioanal Chem (2012) 1.26
Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov (2016) 1.14
Review: toxicometabolomics. J Appl Toxicol (2013) 1.03
Isotopic labeling-assisted metabolomics using LC-MS. Anal Bioanal Chem (2012) 1.02
Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra. J Biomol NMR (2011) 1.00
Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos (2010) 0.97
Xenobiotic metabolism: a view through the metabolometer. Chem Res Toxicol (2010) 0.96
Elucidation of functions of human cytochrome P450 enzymes: identification of endogenous substrates in tissue extracts using metabolomic and isotopic labeling approaches. Anal Chem (2009) 0.96
Applications of NMR spectroscopy to systems biochemistry. Prog Nucl Magn Reson Spectrosc (2016) 0.95
Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol (2011) 0.92
Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice. Hepatology (2011) 0.90
Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol (2011) 0.89
Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology. J Proteome Res (2013) 0.89
Identification of N-acetyltaurine as a novel metabolite of ethanol through metabolomics-guided biochemical analysis. J Biol Chem (2012) 0.87
Towards polypharmacokinetics: pharmacokinetics of multicomponent drugs and herbal medicines using a metabolomics approach. Evid Based Complement Alternat Med (2013) 0.87
Stable isotope-labeled tracers for metabolic pathway elucidation by GC-MS and FT-MS. Methods Mol Biol (2014) 0.87
Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. J Proteome Res (2013) 0.86
Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics (2011) 0.86
Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J Lipid Res (2009) 0.86
Human cytochrome P450 4F11: heterologous expression in bacteria, purification, and characterization of catalytic function. Arch Biochem Biophys (2009) 0.85
Dansylation of unactivated alcohols for improved mass spectral sensitivity and application to analysis of cytochrome P450 oxidation products in tissue extracts. Anal Chem (2010) 0.85
Characterization of differential cocaine metabolism in mouse and rat through metabolomics-guided metabolite profiling. Drug Metab Dispos (2012) 0.84
Potential role of CYP2D6 in the central nervous system. Xenobiotica (2013) 0.84
Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. J Lipid Res (2012) 0.84
Ion annotation-assisted analysis of LC-MS based metabolomic experiment. Proteome Sci (2012) 0.82
LC-MS-based Metabolomics of Xenobiotic-induced Toxicities. Comput Struct Biotechnol J (2013) 0.82
Exploring metabolic pathway disruption in the subchronic phencyclidine model of schizophrenia with the Generalized Singular Value Decomposition. BMC Syst Biol (2011) 0.82
GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats. Acta Pharmacol Sin (2011) 0.81
LC-MS Based Detection of Differential Protein Expression. J Proteomics Bioinform (2009) 0.80
Emerging applications of metabolomics in studying chemopreventive phytochemicals. AAPS J (2013) 0.79
Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opin Drug Metab Toxicol (2015) 0.79
Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC-ESI/MS. Chromatographia (2014) 0.78
Metabolomic Applications in Radiation Biodosimetry: Exploring Radiation Effects Through Small Molecules. Int J Radiat Biol (2017) 0.77
New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS. Xenobiotica (2009) 0.77
Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice. J Pineal Res (2010) 0.77
Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping. Toxicol Sci (2013) 0.76
Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii. Sci Rep (2017) 0.75
Prioritization of putative metabolite identifications in LC-MS/MS experiments using a computational pipeline. Proteomics (2013) 0.75
Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol. Antimicrob Agents Chemother (2016) 0.75
Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics (2016) 0.75
A Metabolomic Strategy to Screen the Prototype Components and Metabolites of Shuang-Huang-Lian Injection in Human Serum by Ultra Performance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry. J Anal Methods Chem (2014) 0.75
Ayurnutrigenomics: Ayurveda-inspired personalized nutrition from inception to evidence. J Tradit Complement Med (2015) 0.75
Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. Int J Mol Sci (2017) 0.75
Separation technique for the determination of highly polar metabolites in biological samples. Metabolites (2012) 0.75
Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance. Front Microbiol (2015) 0.75
Metabolomics revealed diurnal heat stress and zinc supplementation-induced changes in amino acid, lipid, and microbial metabolism. Physiol Rep (2016) 0.75
In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes. Int J Mol Sci (2017) 0.75
Exposure Marker Discovery of Phthalates Using Mass Spectrometry. Mass Spectrom (Tokyo) (2017) 0.75
HMDB: the Human Metabolome Database. Nucleic Acids Res (2007) 13.38
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol (2001) 4.78
Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 4.46
Chemometrics in metabonomics. J Proteome Res (2007) 4.02
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 3.69
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res (2000) 3.32
Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol (2004) 3.31
Data processing for mass spectrometry-based metabolomics. J Chromatogr A (2007) 3.21
Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol (2004) 2.47
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res (2007) 2.08
Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem (2003) 2.07
Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem (2007) 1.99
High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res (2005) 1.93
When good drugs go bad. Nature (2007) 1.85
The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci (2006) 1.63
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene (2006) 1.62
Plant metabolomics: towards biological function and mechanism. Trends Plant Sci (2006) 1.61
Stable isotope labeling of Arabidopsis thaliana for an NMR-based metabolomics approach. Plant Cell Physiol (2004) 1.59
Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci (1978) 1.55
Microbial metabolomics: replacing trial-and-error by the unbiased selection and ranking of targets. J Ind Microbiol Biotechnol (2005) 1.54
Normalization method for metabolomics data using optimal selection of multiple internal standards. BMC Bioinformatics (2007) 1.50
Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol (2006) 1.36
Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther (2006) 1.33
Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun Mass Spectrom (2003) 1.29
A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol (2006) 1.26
Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics (2006) 1.19
A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol (2007) 1.17
Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos (2006) 1.15
Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos (1976) 1.13
Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos (1993) 1.12
The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem Pharmacol (2006) 1.06
High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol (2007) 1.05
Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica (1976) 1.04
Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci (2006) 0.97
Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol (2005) 0.97
Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab (2003) 0.94
Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun Mass Spectrom (2005) 0.93
Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev (2003) 0.93
Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev (2007) 0.92
Cytochrome P450 humanised mice. Hum Genomics (2004) 0.85
The fate of acetanilide in man. J Pharmacol Exp Ther (1948) 0.84
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Drug Metab Dispos (2006) 0.83
Achievement of a 920-MHz high resolution NMR. J Magn Reson (2002) 0.81
1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos (1998) 0.79
Drug metabolite identification: stable isotope methods. J Clin Pharmacol (1986) 0.78
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 1.76
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl) (2005) 1.71
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol (2005) 1.71
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol (2008) 1.69
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest (2008) 1.68
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med (2013) 1.67
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab (2008) 1.65
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal (2005) 1.64
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol (2007) 1.62
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther (2008) 1.62
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem (2002) 1.60
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol (2003) 1.60
Enzymatic mechanisms of ethanol oxidation in the brain. Alcohol Clin Exp Res (2006) 1.59
Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res (2009) 1.59
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology (2008) 1.57
Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes (2011) 1.56
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest (2014) 1.55
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest (2008) 1.55
PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens (2005) 1.55
The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci (2005) 1.54
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res (2007) 1.54
Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem (2005) 1.54
Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) (2008) 1.53
Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol (2006) 1.53
Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol (2009) 1.52
Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta (2009) 1.51
Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol (2007) 1.50
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.50
Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem (2002) 1.48
Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem (2007) 1.47